Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting

Immunic, Inc. (Nasdaq: IMUX) has announced the acceptance of four abstracts for presentation at the MSToronto2026 conference, which will take place from October 21-23, 2026, in Toronto, Canada. The abstracts will focus on new clinical, biomarker, and preclinical data related to Immunic's lead investigational asset, vidofludimus calcium (IMU-838). These abstracts will be published in the online supplement of the Multiple Sclerosis Journal and will be accessible through the conference's digital platforms. Immunic representatives will also be present at the event to engage with attendees at booth #516.